CIC
PRME icon

Cornercap Investment Counsel’s Prime Medicine PRME Stock Holding History

Cornercap Investment Counsel’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-28,923
Closed -$149K – 623
2024
Q2 		$149K Sell
28,923
-318
-1% -$1.93K 0.02% 556
2024
Q1 		$205K Buy
+29,241
New +$222K 0.03% 562

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Cornercap Investment Counsel's PRME Position: Q3 2024 in Review

Cornercap Investment Counsel sold out of Prime Medicine (PRME) in Q3 2024, closing a stake of 28,923 shares — an estimated $149K sold.

Cornercap Investment Counsel first reported a position in PRME in Q1 2024 and held it in 2 quarters. The position peaked at $205K in Q1 2024. 116 funds tracked by Wall St. Rank hold PRME as of Q3 2024.

  • Cornercap Investment Counsel reported no remaining Prime Medicine position as of Q3 2024 after selling out during the quarter.
  • Cornercap Investment Counsel sold 28,923 Prime Medicine shares in Q3 2024, an estimated $149K.
  • Cornercap Investment Counsel first reported a position in Prime Medicine in Q1 2024 and held it in 2 quarters.
  • Cornercap Investment Counsel's Prime Medicine position peaked at $205K in Q1 2024.
  • 116 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2024.

Based on Cornercap Investment Counsel's 13F filing for Q3 2024, filed 6 Nov 2024.